ArticleJournal, genetic engineering & biotechnology2026
Evaluation of CRISPR/Cas9 based single and multiplex gRNAs against ChiLCV in tobacco.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chilli leaf curl virus (ChiLCV), a whitefly-transmitted monopartite begomovirus, causes severe yield losses in chilli-growing regions worldwide. This study evaluated the efficiency of single and multiplex CRISPR/Cas9 gRNAs in targeting key coding regions of ChiLCV genome in Nicotiana benthamiana. Four guide RNAs (gRNAs) specific to the CP, C3/C2, C2/C1, and Rep coding regions, were designed and assembled into four single-gRNA expression constructs, each targeting one viral region at a time, and six dual-gRNA constructs, each simultaneously targeting two viral regions. Agroinfiltration assays showed that all constructs reduced viral DNA, with dual-gRNA combinations achieving stronger suppression than single gRNAs. The gRNA1 + gRNA4 dual combination, targeting CP and Rep genes, was the most effective, reducing viral titre by 49.3% at 4 dpi and 47.9% at 20 dpi in systemic leaves. Viral accumulation was quantified using qPCR, disease severity was assessed phenotypically, and gRNA/Cas9 expression was confirmed by qRT-PCR, while HRM analysis verified targeted genome modifications. Overall, the results demonstrate that dual-gRNA constructs efficiently suppress viral replication, reduce disease severity, and induce precise genome edits, underscoring the potential of multiplexed CRISPR/Cas9 for developing durable resistance against ChiLCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.